Table 2.
Peptide-based immunotherapy.
| Authors | Stage | Vaccine | Adjuvant | Patients | Duration of PFS/RFS | Results |
|---|---|---|---|---|---|---|
| Uemura | mRCC | CA9-derived peptide | Incomplete Freund's adjuvant | 23 | 12.2 mo | 3 PR, 6SD |
| Iiyama | mRCC | WT 1-peptide | Incomplete Freund's adjuvant | 3 | — | 2 SD |
| Suekane | mRCC | 4 different peptides | None, IFN-α, IL-2 | 10 | 23 wk | 6 SD |
| Wood | cT1b-T4N0M0 or T ant N1-2 M0 | HSPPC-96 (vitespen) | None | 728 | 1.9 yr | No difference in recurrence-free survival |
| Jonasch | mRCC | HSPPC-96 (vitespen) | None | 60 | 65 dy | 2 CR, 2 PR, 7 SD |
mRCC: metastatic RCC, PADRE: pan-MHC class II binding peptide, Auto mDC: autologous mature DC, CR: complete response, PR: partial response, SD: stable disease, PFS: progression-free survival, RFS: recurrence-free survival.